Drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There's even a "uni-drug" that may fight many forms of the disease.
Jun 5, 2017
1
151
About half of patients diagnosed with high blood pressure will need their medication adjusted within the first year to address side effects or failure to control blood pressure properly. Among the modification options available, ...
May 30, 2017
0
2
Researchers have developed a test that can rapidly and reliably diagnose sepsis, a potentially life-threatening complication of bacterial infections.
May 17, 2017
0
1
Psychoactive substances are becoming increasingly available to individuals for treating mental health disorders and enhancing cognition, as well as for purposes of creativity, inner exploration, and enjoyment. A new review ...
Apr 20, 2017
0
2
(HealthDay)—Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk ...
Mar 28, 2017
0
0
Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease. But in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other ...
Mar 24, 2017
0
0
(HealthDay)—America's weight problem extends to its pets, with a majority of cats and dogs dangerously overweight, a federal government veterinarian warns.
Mar 16, 2017
0
1
New more effective treatments for high blood pressure could be possible thanks to the discovery that the nitric oxide that regulates blood pressure is formed in nerves rather than in the walls of blood vessels.
Mar 6, 2017
0
48
Obstructive sleep apnea, which causes people to briefly stop breathing while asleep, affects an estimated 5 percent of the population, not including the many more who don't even realize they suffer from the disorder.
Feb 24, 2017
3
284
US pharmaceuticals giant Johnson & Johnson on Thursday announced it was buying Europe's biggest bio-pharmaceutical firm Actelion for $30 billion (27.9 billion euros) in a deal that creates a new spin-off company.
Jan 26, 2017
0
1
